New Health Sciences has big plans.
The Bethesda biotech is eyeing a $310 million revenue stream after 2015 should its storage system for red blood cells pass its clinical trials. And CEO Martin Cannon envisions a potential stock sale of $30 million, should the company go public in the next few years.
Cannon was among the Maryland bioscience executives sharing their success stories, due in part to federal funding, during the National Heart Lung and Blood Institute’s Innovation Conference on Monday at Johns Hopkins University’s Rockville campus.
The gathering was hosted by BioHealth Innovation, a Rockville nonprofit private-public partnership that links bioscience companies and research institutions, and Prescience International of San Francisco.